Davide Rossi, Scientific Editor Blood Cancer Discovery, introduces #ctDNA in #lymphoma detection, Dx, genotyping, & monitoring referencing (his) BCD review by Mark Roschewski et al at #17ICML. bit.ly/3gAMLUe

TEDDI-R in PCNSL Mark Roschewski #17ICML - adapteD to ibr response - 50 pts (30% age>70, 56% synchronous, most R/R) - no aspergillus (antifungals), 30% HFS with doxil - 1-yr PFS 38%, OS 60% Can be given outpatient in sick/older pts. OS high b/c VIPER off protocol after PD. #lymsm

And the message that R-CHOP seems inferior (or requires more RT) in PMBCL is important!

ICML highlights. EOT MRD predicts outcome in DLBCL Australasian Leukaemia & Lymphoma Group (ALLG) Ash Alizadeh, MD/PhD 🇺🇸 Mark Hertzberg Mark Roschewski

Congratulations to Mark Roschewski and his team for their abstract recognitions at International Conference on Malignant Lymphoma in Switzerland last week! CCR Lymphoma #17ICML 👏 Check out the full list of authors and learn more here: icml.ch/icml/17th-icml…

#ESHLYMPHOID2023 ONLY 2 WEEKS LEFT TO SUBMIT YOUR ABSTRACT! Proceed now ➡ bit.ly/3Uj3XQ7 🗓️ Oct. 20-22, 2023 in Estoril 🇵🇹 7th Translational Research Conference: #LYMPHOID MALIGNANCIES Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt #ESHCONFERENCES #Lymsm

Great read on the future of ctDNA for lymphoma

Here it is: a new article on ctDNA in lymphoma Is a New Era Dawning for ctDNA in Lymphoma? bloodcancerstoday.com//post/is-a-new…

To conclude, the effect of DLBCL cell of origin on polatuzumab efficacy was established by prior studies, & confirmed by 2 RCTs. Should this now inform precision medicine in DLBCL? 12/EOT. #lymsm Lymphoma Research Foundation The Leukemia & Lymphoma Society Lymphoma Hub Andrew M. Evens, DO, MBA, MSc David Russler-Germain, MD/PhD Matthew J. Maurer, DMSc Mark Roschewski

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL Mark Roschewski National Cancer Institute Society of Hematologic Oncology (SOHO) #SOHO2023 #hematology ow.ly/IzH550PIYOK

#ctDNA may soon be effectively used to improve upon imaging scans to detect active large cell lymphoma at the end of treatment. #SOHO23 #lymsm | Mark Roschewski National Cancer Institute READ MORE: ow.ly/aOTW50PIX0m

Recommended reading: REVIEW ARTICLES Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy Daniel Hodson Mark Roschewski Haematologica #SCNSL Early View | Haematologica haematologica.org/article/view/h…

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today nature. #lymsm 1/15 nature.com/articles/s4158… PDF link at bottom of this thread

"Mark Roschewski and his colleagues at the NCI speculated that a determination of MRD via ...PhasED-seq could provide a more reliable and complementary method for identifying the lymphoma patients that don't need further salvage therapy." #ASH23 GenomeWeb t.ly/bKQ2_

BTK is known for its role in BCR signaling & BTKi transformed the therapy of lymphoid malignancies. But why do BTKi cause fungal disease? We show that BTK drives neutrophil antifungal activity via p40phox and RAC2 activation; GMCSF rescues BTKi PMN defects jci.org/articles/view/…

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma | New England Journal of Medicine nejm.org/doi/full/10.10… Concept by Wyndham Wilson, pre-clinical rationale by Lou Staudt, and study led by Christopher Melani . Thanks to all patients.

hmpgloballearningnetwork.com/site/onc/confe…

New work from the Lymphoid Malignancies Branch shows that loss of Ga13 drives B cell lymphomas preferentially in the mesenteric lymph nodes. Ga13 is required to counteract mTORC1 and Myc signaling that is driven by the availability of dietary glutamine. rdcu.be/dORlh

Work from the Lymphoid Malignancies Branch reveals that ARID1A and SWI/SNF activity are required for IRF4-dependent transcription. Inhibition of SWI/SNF blocks plasma cell development and is toxic to myeloma cells.sciencedirect.com/science/articl…

Please join me for @KarmanosCancerInstitute’s Sixth Annual Lymphoma Symposium on Aug. 3 at Detroit Marriott Troy. I will be presenting on Primary CNS Lymphoma. Register online by Aug. 1 by visiting karmanos.org/lymphomasympos…